Welcome to our dedicated page for ImageneBio SEC filings (Ticker: IMA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The ImageneBio, Inc. (neBio, Inc., Nasdaq: IMA) SEC filings page on Stock Titan aggregates the company’s U.S. regulatory disclosures, giving investors direct access to official information about this clinical-stage biotechnology issuer. neBio focuses on therapeutics for immunological, autoimmune, and inflammatory diseases, and its filings provide context on the development of its lead asset, -007, an investigational non-depleting anti-OX40 monoclonal antibody.
Through this page, users can review current reports on Form 8-K that document material events such as the completion and subsequent amendment of the merger between Inmagene Biopharmaceuticals and Ikena Oncology, Inc., changes in executive officers and directors, entry into or modification of material agreements, and the announcement of quarterly financial results. These filings also confirm that neBio’s common stock, with a par value of $0.001 per share, is registered under Section 12(b) of the Exchange Act and trades on The Nasdaq Capital Market under the symbol IMA.
Investors can also locate neBio’s registration statement on Form S-1, which contains detailed descriptions of the company’s business, risk factors, and financial statements, including discussion of how historical financial data were adjusted to reflect the recapitalization associated with the merger. As the company advances -007 through clinical development, periodic and current reports provide additional insight into research and development spending, corporate structure, and key risk disclosures.
Stock Titan enhances these filings with AI-powered summaries that explain the significance of each document in accessible language. Users can quickly understand the main points of lengthy reports while retaining the option to open the full SEC filing text for deeper review, helping them follow IMA’s regulatory and corporate history with less manual effort.
ImageneBio, Inc. filed an initial insider ownership report for Benjamin Porter-Brown, who serves as Chief Medical Officer. This Form 3 does not list any share transactions or holdings, but formally registers his status as an officer subject to insider reporting rules.
ImageneBio, Inc. files a prospectus supplement registering 2,508,337 shares of common stock for resale by selling stockholders. The supplement incorporates parts of a Form 8-K dated
The supplement states the last reported sales price was
ImageneBio, Inc. reported that Steven Hui Wang resigned from its Board of Directors, effective immediately on February 12, 2026. The company stated that his resignation was not due to any disagreement with ImageneBio regarding its operations, policies, practices, or strategy. The filing otherwise reflects routine corporate and listing information, including that ImageneBio’s common stock trades on the Nasdaq Capital Market under the symbol IMA.
Imagenebio, Inc. received an amended Schedule 13G showing that Deep Track Capital, Deep Track Biotechnology Master Fund, Ltd., and David Kroin now report zero beneficial ownership of the company’s common stock. Each reporting person lists 0 shares with 0% of the class and no voting or dispositive power. The filing confirms they own 5 percent or less of Imagenebio’s common stock. The ownership calculations use 11,181,672 shares outstanding as of November 3, 2025, as disclosed in Imagenebio’s prior quarterly report.
ImageneBio, Inc. received a Schedule 13G filing showing that Blue Owl Capital Holdings LP beneficially owns 823,785 shares of ImageneBio common stock. This represents 7.37% of the company’s outstanding common shares, based on 11,181,672 shares reported as outstanding as of November 3, 2025.
Blue Owl reports sole voting and dispositive power over all 823,785 shares and no shared power. The firm certifies that the shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of ImageneBio.
ImageneBio, Inc. has filed a prospectus supplement covering the proposed offer and resale from time to time by selling stockholders of 2,508,337 shares of common stock. The supplement incorporates information from a recent current report that notes Chief Medical Officer Yufang Lu, M.D., Ph.D. has notified the company of her resignation, effective December 31, 2025. The company states that her resignation is not due to any disagreement related to operations, policies or practices. ImageneBio is conducting a search for her replacement, and Dr. Lu is expected to provide transition advisory services after her resignation date. The company’s common stock trades on the Nasdaq Capital Market under the symbol IMA, and last traded at $6.24 per share on December 17, 2025.
Imagenebio, Inc. reported that its Chief Medical Officer, Yufang Lu, M.D., Ph.D., has given notice of her resignation effective December 31, 2025. The company states that Dr. Lu’s decision is not due to any disagreement regarding its operations, policies, or practices, which suggests the change is not driven by internal conflict.
Imagenebio is beginning a search for a new Chief Medical Officer, an important role overseeing its medical and clinical programs. Dr. Lu is expected to provide transition advisory services after her resignation date, helping to maintain continuity in the company’s clinical and medical activities while leadership responsibilities are handed over to her eventual successor.
IMAGENEBIO, INC. (IMA) filed a current report to announce that it has updated its corporate presentation for use in meetings with investors, analysts and other interested parties. The updated presentation, dated November 19, 2025, is being made available on the company’s website and is also included as Exhibit 99.1 to this report.
The company notes that the information in this investor presentation and in this report under Item 7.01 is being furnished rather than filed under securities laws, which means it is not automatically incorporated into other securities filings unless specifically referenced there.
ImageneBio, Inc. (IMA) filed a Form S-8 to register new shares for employee and equity plans. The filing covers 1,118,167 shares of common stock issuable under the ImageneBio, Inc. 2025 Equity Incentive Plan, 111,816 shares under the 2025 Employee Stock Purchase Plan, 589,585 shares under the 2025 Equity Inducement Plan, and 455,938 shares under the Inmagene Biopharmaceuticals 2019 Stock Incentive Plan.
The company notes it completed a merger on July 25, 2025, after which it assumed Legacy Inmagene’s 2019 Stock Incentive Plan and converted outstanding options into options for ImageneBio common stock. The filing also describes standard Delaware-law indemnification for directors and officers, the company’s charter and bylaw protections, and related insurance coverage. This registration facilitates future issuances to employees, directors, and other service providers pursuant to the specified plans.
ImageneBio, Inc. filed a prospectus supplement covering the proposed offer and resale, from time to time, by selling stockholders of 2,508,337 shares of common stock.
The supplement updates the base prospectus by attaching the company’s Quarterly Report on Form 10-Q filed on November 12, 2025. ImageneBio’s common stock trades on the Nasdaq Capital Market under the ticker IMA; the last reported sales price was $8.61 per share on November 11, 2025. The filing reiterates that investing in the securities involves a high degree of risk, directing readers to the Risk Factors in the prospectus.